Bioidentical vs Synthetic HRT: What's the Actual Difference?

Bioidentical means the hormone molecule is chemically identical to the one your body naturally makes. For estrogen, that is 17-beta-estradiol — the same structure your ovaries produce. For progesterone, that is micronized progesterone — the same molecule found in the corpus luteum after ovulation. Bioidentical hormones can be synthesized in a lab (most are derived from plant sterols in soy or yam, then chemically modified), but the end product is structurally indistinguishable from human hormones.

Synthetic, in HRT terminology, refers to hormones that are not chemically identical to human hormones. Conjugated equine estrogens (Premarin) are derived from pregnant mare urine and contain a mix of estrogens, some of which do not exist in the human body. Medroxyprogesterone acetate (Provera) is a chemically altered progestin that binds the progesterone receptor but has additional effects on androgen and glucocorticoid receptors that natural progesterone does not.

The distinction matters because the body processes these molecules differently. Bioidentical hormones engage the receptors they were designed to engage. Synthetic versions can have off-target effects — which is the main reason the safety profiles differ.

The differences fall into three buckets: chemical structure, side effect profile, and how they are absorbed. The chemical difference drives the other two — but the route of administration (oral vs transdermal) often matters as much or more than the molecule itself. The table below shows the key contrasts.

Bioidentical HRT is generally considered safer than older synthetic combinations — but the picture is more nuanced than the marketing suggests. The improved safety comes from two things, only one of which is the molecule itself. The other is the route of administration. Most modern HRT is bioidentical *and* transdermal (patch or gel), and the transdermal route bypasses the liver, which is where oral hormones generate clotting factors and inflammation markers. The KEEPS trial (Kronos Early Estrogen Prevention Study) and observational data from the E3N French cohort found transdermal bioidentical estradiol with micronized progesterone did not raise venous clot risk, while oral conjugated equine estrogens nearly doubled it.

Breast cancer risk also separates by progestin choice. The WHI (Women's Health Initiative) showed an increased breast cancer signal with conjugated equine estrogens combined with medroxyprogesterone acetate (Prempro). When the progesterone is micronized natural progesterone instead of MPA, the breast cancer signal in observational studies is much smaller — and in some cohorts, not statistically significant. That is one reason micronized progesterone has become the preferred option for women with a uterus. For the practical decisions on form factor, our piece on [HRT delivery methods compared](/blog/hrt-patch-vs-gel-vs-pill-which-delivery-method-is-best) walks through the trade-offs of patch versus gel versus pill.

Compounded bioidentical hormone therapy (cBHT) is a separate category that deserves its own caveats. Compounded means a pharmacy mixes the formulation from raw hormones — usually in a cream, troche, pellet, or injection — based on a clinician's prescription, often after a saliva or blood test purports to identify your unique hormone needs. The marketing emphasizes "natural," "customized," and "individualized." The reality is more complicated.

The National Academies of Sciences, Engineering, and Medicine (NASEM) 2020 report on compounded bioidentical hormone therapy concluded that there is insufficient evidence to support claims of superior safety or efficacy compared to FDA-approved bioidentical hormones, and that compounded preparations carry real risks: inconsistent dosing (different from prescription to prescription, sometimes by 30%+), no FDA quality control, no required clinical trials for efficacy, and reliance on saliva tests that do not reliably reflect tissue-level hormone activity. Pellet implants — increasingly marketed by anti-aging clinics — frequently deliver supraphysiologic doses that may worsen rather than help symptoms.

If you want bioidentical hormones, the FDA-approved versions are bioidentical — Climara, Vivelle-Dot, Divigel, EstroGel for estradiol; Prometrium and Mimvey for micronized progesterone. There is rarely a clinical reason to use a compounded version unless you have a documented allergy to an inactive ingredient.

A clear list helps cut through marketing language. FDA-approved bioidentical estrogens include the Climara patch, Vivelle-Dot, Minivelle, Divigel, EstroGel, Estrace tablets, and Estring vaginal ring — all 17-beta-estradiol. FDA-approved bioidentical progesterone includes Prometrium (the original) and several generic micronized progesterone capsules. Combination products like Bijuva and Mimvey deliver bioidentical estradiol plus bioidentical progesterone in a single pill or patch.

What is not bioidentical in the FDA-approved category: Premarin (conjugated equine estrogens), Provera (medroxyprogesterone acetate), Prempro (the combination), and most older birth control pills used off-label for menopause symptoms. These remain on the market and have their place — they are well-studied and effective — but they are not interchangeable with bioidentical alternatives.

For [testosterone in women](/blog/testosterone-for-women-menopause-the-missing-hormone) — increasingly part of HRT protocols — the FDA has not yet approved a testosterone product for women in the US, so all current options are off-label use of male-dose products at compounded lower doses. This is the one area where carefully compounded testosterone has a defensible role in current practice, while the regulatory framework catches up.

For most women starting HRT in 2026, the choice is straightforward: FDA-approved bioidentical estradiol (transdermal patch or gel) plus micronized progesterone (oral, at bedtime) if you have a uterus. This is what the Menopause Society 2022 Position Statement recommends as first-line for most women under 60 or within 10 years of menopause onset. The [timing window for starting HRT](/blog/when-to-start-hrt-timing-and-the-window-of-opportunity) is one of the most important factors in determining whether HRT helps or harms — the molecule choice matters less than the timing.

Reasons to consider synthetic options anyway: insurance only covers Premarin (rare but happens), you have tolerated Prempro well for years and are stable, or you have specific bleeding patterns that respond better to MPA. Reasons to actively avoid synthetic combinations: personal history of breast cancer, history of clotting disorders, migraine with aura, or a strong preference for the lowest measurable risk profile available.

Bring three questions to your appointment. First: "What molecule are you prescribing — estradiol or conjugated estrogens?" Second: "What progesterone are you using — micronized progesterone or medroxyprogesterone acetate?" Third: "What delivery route — patch, gel, pill?" The answers to these three questions tell you exactly what you are taking and whether it fits the current safety evidence.

If your provider hands you a prescription for compounded pellet HRT, ask why an FDA-approved equivalent will not work. The honest answer for most cases is that one would. The exception, currently, is testosterone — for which compounded preparations remain the standard of care for women in the US until the FDA approves a women's product.